Last reviewed · How we verify

Bay F 4975 — Competitive Intelligence Brief

Bay F 4975 (ACEMETACIN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: acemetacin. Area: Immunology.

phase 2 acemetacin Lactoylglutathione lyase Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Bay F 4975 (ACEMETACIN). Acemetacin works by inhibiting the enzyme lactoylglutathione lyase, which is involved in the breakdown of certain inflammatory mediators.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bay F 4975 TARGET ACEMETACIN phase 2 acemetacin Lactoylglutathione lyase
Sulfamethazine sulfadimidine Pfizer marketed sulfadimidine Lactoylglutathione lyase, Dihydropteroate synthase 1949-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (acemetacin class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bay F 4975 — Competitive Intelligence Brief. https://druglandscape.com/ci/acemetacin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing